Q-omics provides the consensus-scored FCF1 profile across patient tissues and cancer cell-line models. FCF1 expression is associated with patient survival in 27 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, FCF1 is differentially expressed in 14, with the highest sampling consensus in HNSC. Additionally, FCF1 RNA expression shows 19,970 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight KIRC, HNSC, and ACC as cancer lineages where FCF1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for FCF1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes FCF1 survival associations across molecular data types. FCF1 RNA expression shows survival associations in the most cancer types (27), followed by mutation status (3) and mass-spec protein abundance (8). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible FCF1 RNA expression–survival associations across cancer types. High FCF1 expression shows unfavorable associations in ACC, PAAD, HNSC, STAD and LIHC, but favorable associations in KIRC. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for FCF1 RNA expression.
This table summarizes FCF1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14, while mass-spec protein shows differences in 9. The strongest signals are observed in HNSC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for FCF1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. FCF1 shows lower tumor expression in THCA and higher tumor expression in HNSC, BLCA, LIHC, KIRP and LUSC. The HNSC box plot shows higher FCF1 RNA expression in tumor versus normal tissue (log2 FC = +1.149, t-test p < 0.001).
This table shows molecular features associated with FCF1 in patient tissues and cancer cell lines. In patient samples, FCF1 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, FCF1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LIVER, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and LARGE_INTESTINE.
